Tag

Naion

All articles tagged with #naion

health1 month ago•3 min saved

Australia flags rare eye risk tied to GLP-1 diabetes/weight drugs

Australia’s TGA warns of a rare but serious eye disorder called NAION linked to GLP-1 medicines such as Ozempic, Wegovy and Mounjaro; 36 cases have been reported (23 with Ozempic/Wegovy, 10 with Mounjaro, 3 with Saxenda), prompting updated safety warnings but no prescription restrictions. Patients should seek urgent medical attention for sudden vision loss, while doctors are advised not to stop treatment without consultation. Novo Nordisk says the benefit–risk profile remains favorable given the drugs’ overall impact on diabetes and obesity.

via The Guardian|

#glp-1 #health #mounjaro

health1 month ago•3 min saved

Rare Eye Risk Prompting Safety Update on GLP-1 Diabetes and Weight Drugs

Australia’s Therapeutic Goods Administration warns GLP-1 receptor agonists used for diabetes and obesity (semaglutide Ozempic/Wegovy, tirzepatide Mounjaro, dulaglutide Trulicity, liraglutide Saxenda) may cause a rare eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION), which can lead to permanent vision loss. Thirty-six cases have been reported in Australia; the warning follows a 2024 JAMA Ophthalmology study that found higher NAION risk with semaglutide. The TGA conducted an independent assessment and consulted experts. Optometry Australia says don’t panic, but seek urgent care if vision changes; risk factors include diabetes, sleep apnea, hypertension, and a crowded optic disc, with about 70% of NAION cases not recovering vision. WHO has endorsed GLP-1–style drugs for obesity; regular eye tests are advised and patients should inform eye doctors of their treatment. Do not stop medication without consulting a prescriber; EMA has noted NAION as a very rare side effect (up to 1 in 10,000).

via ABC News & Headlines – Australian Broadcasting Corporation|

#diabetes-obesity-drugs #eyedisorder #glp-1

health1 month ago•5 min saved

Georgia Woman Alleges GLP-1 Weight-Loss Drug Led to Blindness in Multistate Lawsuit

A Georgia woman says Wegovy caused sudden, irreversible blindness (NAION) and is part of a multi-district lawsuit against Novo Nordisk and Lilly alleging known risks were not disclosed; the companies deny a causal link and highlight ongoing safety reviews, while regulators have not yet added a US warning, and the case is expected to unfold over years.

via WSB-TV|

#blindness #glp-1 #health

health1 month ago•9 min saved

GLP-1 Receptor Agonists: Eye Safety Generally Reassuring Despite Rare Risks

A Medscape commentary from ADA 2026 reviews eye safety of GLP-1 receptor agonists, noting rare associations with nonarteritic anterior ischemic optic neuropathy (NAION) and concerns about rapid worsening of diabetic retinopathy (EWDR). Real-world data and EMA updates suggest the overall benefits of GLP-1s outweigh these small ocular risks, but clinicians should ensure up-to-date retinal screening and advise patients to report visual changes; ongoing trials (eg, FOCUS) and mixed studies on neovascular AMD yield no definitive risk signal. Clinicians are encouraged to individualize care and monitor ocular health when initiating GLP-1 therapy.

via Medscape|

#diabetic-retinopathy #ewdr #eye-safety

science5 months ago•5 min saved

Wegovy May Elevate Rare Eye Stroke Risk, Study Finds

A large look at FDA adverse-event data suggests Wegovy (high-dose semaglutide) has a rare link to NAION, an “eye stroke” that can cause sudden vision loss, with men at higher risk than women. Wegovy shows a stronger association than Ozempic, possibly due to rapid weight loss and blood‑pressure fluctuations, but the overall risk remains very small and more research is needed.

via ScienceAlert|

#eye-stroke #naion #science

health5 months ago•3 min saved

Study ties high-dose Wegovy to fivefold eye-stroke risk versus Ozempic

A study of FDA adverse-event reports (2017–2024) found Wegovy’s high-dose semaglutide for obesity linked to about five times the risk of non-arteritic anterior ischemic optic neuropathy (NAION) compared with Ozempic’s diabetes-dose semaglutide, with men at higher risk than women. Rybelsus and tirzepatide showed no increased risk. The findings are observational and do not prove causation; NAION is rare (roughly 1 in 10,000 on semaglutide). Regulators have issued warnings and Novo Nordisk says the overall benefit–risk profile remains favorable while continuing safety monitoring.

via The Guardian|

#adverse-event-reporting #health #naion

healthcare6 months ago•10 min saved

MHRA warns Ozempic/Wegovy could cause rare eye condition

Britain's MHRA has warned that the diabetes/weight‑loss injections Ozempic (semaglutide) and Wegovy may cause a rare optic nerve condition (NAION) that can lead to sudden vision loss in one eye. The regulator has received three reports, but says the overall risk is very small; with about two million UK users, patients and clinicians are advised to be alert to symptoms and seek urgent eye care if vision changes occur. The warning also notes that pancreatitis is a known but infrequent side effect of GLP-1 weight‑loss drugs.

via The Times|

#healthcare #mhra #naion

law-and-health11 months ago•9 min saved

Ozempic and GLP-1 Drugs: Risks, Trends, and Effectiveness in Weight Loss

Ozempic, a popular drug for weight loss and diabetes, is facing numerous lawsuits due to alleged severe side effects, especially irreversible vision loss from NAION, with regulatory bodies and studies supporting a potential link. The legal battle is intensifying, with significant financial and reputational risks for Novo Nordisk, as plaintiffs share personal stories and courts consider the evidence. The outcome could reshape pharmaceutical accountability and drug safety standards.

via Bored Panda|

#law-and-health #lawsuit #naion

health1 year ago•7 min saved

Rare Vision Loss Risks Linked to Popular Diabetes and Weight Loss Drugs

A Maryland man claims that the popular diabetes and weight loss drug Ozempic caused his sudden, irreversible blindness due to a rare condition called NAION, raising concerns about the drug's safety and the need for clearer warnings. Emerging research and regulatory reviews are investigating the potential link between semaglutide medications and this serious side effect.

via WJLA|

#blindness #diabetes #health

health1 year ago•6 min saved

Risks of Vision Loss Linked to GLP-1 Diabetes Drugs

Recent studies on semaglutide, a GLP-1 medication, show conflicting results regarding its link to eye problems. While some research suggests a possible association with nonarteritic anterior ischemic optic neuropathy (NAION), overall evidence is inconclusive, and the medication appears not to significantly increase the risk of diabetic retinopathy or other eye disorders. Experts recommend ongoing research and regular eye exams for users.

via Medical News Today|

#diabetic-retinopathy #eye-problems #health

health1 year ago•5 min saved

Weight-Loss Drugs and Eye Health: What You Need to Know

Recent studies suggest that GLP-1 agonist drugs like Ozempic and Wegovy, used for weight loss and diabetes management, may carry a small risk of serious eye conditions such as NAION and diabetic retinopathy, but the overall risk appears modest and requires further research. Patients with risk factors should consult their doctors and undergo regular eye exams to monitor eye health while on these medications.

via ScienceAlert|

#diabetic-retinopathy #glp-1-agonists #health

health1 year ago•4 min saved

Weight-loss and Diabetes Drugs Associated with Rare Eye Conditions and Vision Risks

Recent studies suggest that GLP-1 agonists like Ozempic and Wegovy may slightly increase the risk of serious eye conditions such as NAION and diabetic retinopathy, but they also offer significant benefits for managing diabetes and obesity. Regular eye exams and careful risk assessment are recommended for users, especially those with pre-existing risk factors. Ongoing research aims to better understand these risks and improve patient safety.

via The Conversation|

#diabetic-retinopathy #eye-conditions #health

health1 year ago•6 min saved

Semaglutide and Weight Loss Drugs May Increase Risk of Serious Eye Conditions

Novo Nordisk's weight loss drugs Ozempic and Wegovy are linked to rare cases of a serious eye condition called NAION, which can cause vision loss, prompting regulatory updates and further studies on their safety, especially concerning their use in diabetes and obesity treatment.

via CNBC|

#eye-side-effects #health #naion

health1 year ago•1 min saved

Study Links Ozempic to Vision Loss Risk, Novo Nordisk Shares Fall

A non-peer reviewed study suggests a potential link between Novo Nordisk's diabetes drug Ozempic and an increased risk of developing NAION, a rare eye condition causing sudden blindness. The study found that Ozempic users were over twice as likely to develop NAION compared to those on other diabetes medications, though the overall incidence remains low. The findings highlight the need to balance the drug's benefits in managing diabetes and obesity against the potential risk of vision loss.

via Quartz|

#diabetes #health #naion

health1 year ago•2 min saved

Study Confirms Rare Vision Loss Risk with Ozempic

A study has linked Novo Nordisk's diabetes drug Ozempic to an increased risk of a rare vision loss condition called NAION, confirming earlier Harvard research. The study found that diabetes patients using Ozempic were more than twice as likely to develop NAION compared to those on other diabetes medications. Although the overall risk remains low, the condition is irreversible and potentially blinding. Novo Nordisk maintains that the drug's benefits outweigh the risks, as few NAION cases were observed in their trials. The findings have impacted Novo's stock, which fell by 5.4% in Copenhagen.

via Yahoo Finance|

#diabetes #health #naion